France: Carmat revives production of Aeson artificial heart with new share issue

Carmat prosthesis

Artificial heart designer and developer, Carmat, has raised €40.5m (US$43.9m) from the issuance of new shares at €10 per share. It had originally targeted a capital raise of €30m. The company plans to use the funds to ensure the continuity of its activities, to restart the production of its Aeson artificial heart, and ensure the…

You must be a HMI Subscriber to view this content.

Subscribe Now »